Document:

EXHIBIT 4.3

 

[FORM OF REGISTRATION RIGHTS AGREEMENT]

 

THIS REGISTRATION
RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of July 23, 2014, between Skyline
Medical Inc., a Delaware corporation (the “Company”), and [●], a New York limited liability company
(the “Investor”).

 

In connection with
the Securities Purchase Agreement, dated as of July 23, 2014, entered into by the Company and the Investor (the “Securities
Purchase Agreement”), the Company has agreed, upon the terms and subject to the conditions of the Securities Purchase
Agreement, to issue and sell to the Investor (i) a note of the Company (the “Note”), which will, among
other things, be convertible into shares of the Company's common stock, $0.01 par value per share (the ”Common
Stock”) to the Investor (as converted, the “Conversion Shares”) in accordance with the
terms of the Note and (ii) a warrant of the Company (the “Warrant”), which will, among other things,
be exercisable into shares of Common Stock to the Investor (as converted, the “Warrant Shares”) in accordance
with the terms of the Warrant. The Company has also agreed, upon the terms and subject to the conditions of certain other securities
purchase agreements entered into concurrently with the Securities Purchase Agreement, to issue and sell to certain affiliates of
the Company (i) notes of the Company (the “Other Notes” and together with the Note, the “Notes”),
which will, among other things, be convertible into shares of Common Stock to such affiliates (as converted, the “Other
Conversion Shares”) and (ii) warrants of the Company (the “Other Warrants” and together
with the Warrant, the “Warrants”), which will, among other things, be exercisable into shares of Common
Stock to such affiliates (as converted the “Other Warrant Shares”).

 

To induce the Investor
to consummate the transactions contemplated by the Securities Purchase Agreement, the Company has agreed to provide certain registration
rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute
(collectively, the “1933 Act”), and applicable state securities laws.

 

The Company and the
Investor hereby agrees as follows:

 

Section
1.          Definitions. Capitalized terms used and not otherwise
defined herein that are defined in the Securities Purchase Agreement shall have the meanings given such terms in the Securities
Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

 

“Initial
Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
by the SEC pursuant to the 1933 Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements
to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated
by reference in such Prospectus.

 

    	 

    	 

    

 

“Effectiveness
Deadline” means, (i) with respect to the Initial Registration Statement required to be filed hereunder, the earlier
of (A) the 60th calendar day after the date hereof (or the 120th calendar day after the date hereof in the
event that such Registration Statement is subject to review by the SEC) and (B) the fifth Trading Day after the date the Company
is notified (orally or in writing, whichever is earlier) by the SEC that such Registration Statement will not be reviewed or will
not be subject to further review, and (ii) with respect to any additional Registration Statements which may be required pursuant
to Section 2, the earlier of (A) the 60th calendar day following the date on which an additional Registration Statement
is required to be filed hereunder (or the 120th calendar day after the date hereof in the event that such Registration
Statement is subject to review by the SEC) and (B) the fifth Trading Day after the date the Company is notified (orally or in writing,
whichever is earlier) by the SEC that such Registration Statement will not be reviewed or will not be subject to further review.

 

“Filing
Deadline” means, with respect to the Initial Registration Statement required hereunder, the 45th calendar
day following the date hereof and, with respect to any additional Registration Statements which may be required pursuant to Section
2, the earliest practical date on which the Company is permitted to file such additional Registration Statement related to the
Registrable Securities (taking into account any Staff position with respect to date on which the Staff will permit such additional
Registration Statement to be filed with the SEC).

 

“Other
Registrable Securities” means, as of any date of determination, (a) all Other Conversion Shares then issuable upon
conversion in full of the Other Notes (assuming on such date the Other Notes are converted in full without regard to any conversion
limitations therein), (b) all Other Warrant Shares then issuable upon exercise in full of the Other Warrants (assuming on such
date the Other Warrants are exercised in full without regard to any exercise limitations therein), and (c) any securities issued
or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing;
provided, however, that any such Other Registrable Securities shall cease to be Other Registrable Securities for so long as (x)
a Registration Statement with respect to the sale of such Other Registrable Securities is declared effective by the SEC under
the 1933 Act and such Other Registrable Securities have been disposed of in accordance with such effective Registration Statement,
or (y) such Other Registrable Securities have been previously sold in accordance with Rule 144.

 

“Registrable
Securities” means, as of any date of determination, (a) all Conversion Shares then issuable upon conversion in full
of the Note (assuming on such date the Note is converted in full without regard to any conversion limitations therein), (b) all
Warrant Shares then issuable upon exercise in full of the Warrant (assuming on such date the Warrant is exercised in full without
regard to any exercise limitations therein), and (c) any securities issued or then issuable upon any stock split, dividend or other
distribution, recapitalization or similar event with respect to the foregoing; provided, however, that any such Registrable Securities
shall cease to be Registrable Securities for so long as (x) a Registration Statement with respect to the sale of such Registrable
Securities is declared effective by the SEC under the 1933 Act and such Registrable Securities have been disposed of in accordance
with such effective Registration Statement, or (y) such Registrable Securities have been previously sold in accordance with Rule
144.

 

    	2

    	 

    

 

“Registration
Statement” means any registration statement required to be filed hereunder pursuant to Section 2, including (in each
case) the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective
amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such
registration statement.

 

“Rule
144” means Rule 144 promulgated by the SEC pursuant to the 1933 Act, as such rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such rule.

 

“Rule
415” means Rule 415 promulgated by the SEC pursuant to the 1933 Act, as such Rule may be amended or interpreted from
time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as
such Rule.

 

“SEC”
means the United States Securities and Exchange Commission.

 

Section
2.          Registration Statement Requirements.

 

(a)          The
Company shall prepare and, as soon as practicable, but in no event later than the Filing Deadline, file with the SEC the Initial
Registration Statement on Form S-1, or such other form reasonably acceptable to the Investor, covering the resale by the Investor
of all or such portion of the Registrable Securities (as determined on the date of such filing and the effective date of such Registration
Statement, as applicable) as permitted by the SEC (provided that the Company shall use reasonably diligent efforts to advocate
with the SEC for the registration of all of the Registrable Securities) pursuant to Rule 415. In no event shall the Company include
any securities other than Registrable Securities or the Other Registrable Securities on any Registration Statement pursuant to
this Section 2 without the prior written consent of the Investor. The Company shall use its reasonable best efforts to have such
Initial Registration Statement, and each other Registration Statement required to be filed pursuant to the terms hereof, declared
effective by the SEC as soon as practicable, but in no event later than the applicable Effectiveness Deadline. If at any time all
Registrable Securities are not covered by the Initial Registration Statement filed pursuant to this Section 2, the Company shall
file with the SEC one or more additional Registration Statements so as to cover all of the Registrable Securities not covered by
the Initial Registration Statement, in each case, as soon as practicable (taking into account any Staff position with respect to
date on which the Staff will permit such additional Registration Statement(s) to be filed with the SEC), but in no event later
than the applicable Filing Deadline for such additional Registration Statement(s). By 9:30 a.m. New York time on the Business Day
following the effective date of each Registration Statement filed in accordance herewith, the Company shall file with the SEC in
accordance with Rule 424 under the 1933 Act the final prospectus to be used in connection with sales pursuant to such Initial Registration
Statement. The Company shall not be required to keep such Registration Statements filed in connection herewith effective (and the
prospectus contained therein available for use) after the earlier of (i) the date as of which the Investor may sell all of the
Registrable Securities required to be covered by such Registration Statement without restriction pursuant to Rule 144 (including,
without limitation, volume restrictions) and without the need for current public information required by Rule 144(c)(1) (or Rule
144(i)(2), if applicable) or (ii) the date on which the Investor shall have sold all of the Registrable Securities either pursuant
to a Registration Statement or Rule 144 (such earlier date, the “Registration Rights Expiration Date”,
and such period commencing on the date hereof and ending on the Registration Rights Expiration Date, the “Registration
Period”).

 

    	3

    	 

    

 

(b)          If
the staff of the SEC (the “Staff”) or the SEC seeks to characterize any offering pursuant to a Registration
Statement filed pursuant to this Agreement as constituting an offering of securities that does not permit such Registration Statement
to become effective and be used for resales by the Investor on a delayed or continuous basis under Rule 415 at then-prevailing
market prices (and not fixed prices) (or as otherwise may be reasonably acceptable to the Investor), or if after the filing of
the Initial Registration Statement with the SEC pursuant to this Section 2, the Company is otherwise required by the Staff or the
SEC to reduce the number of Registrable Securities included in such Initial Registration Statement, then the Company shall reduce
the number of Registrable Securities to be included in such Initial Registration Statement (with the prior consent, not to be unreasonably
withheld, of the Investor as to the specific Registrable Securities to be removed therefrom) until such time as the Staff and the
SEC shall so permit such Registration Statement to become effective and be used as aforesaid. Notwithstanding anything in this
Agreement to the contrary, if after giving effect to the actions referred to in the immediately preceding sentence, the Staff or
the SEC does not permit such Registration Statement to become effective and be used for resales by the Investor on a delayed or
continuous basis under Rule 415 at then-prevailing market prices (and not fixed prices) (or as otherwise may be reasonably acceptable
to the Investor), the Company shall not request acceleration of the effective date of such Registration Statement, the Company
shall promptly (but in no event later than 48 hours) request the withdrawal of such Registration Statement pursuant to Rule 477
under the 1933 Act. In the event of any reduction in Registrable Securities pursuant to this paragraph, the Company shall file
additional Registration Statements as permitted by the Staff or the SEC in accordance with this Section 2 until such time as all
Registrable Securities have been included in Registration Statements that have been declared effective and the prospectus contained
therein is available for use by the Investor.

 

(c)          In
addition, in the event that the Staff or the SEC requires the Investor seeking to resell securities under a Registration Statement
filed pursuant to this Agreement to be specifically identified as an “underwriter” in order to permit such
Registration Statement to become effective, and the Investor does not consent to being so named as an underwriter in such Registration
Statement, then, in each such case, the Company shall reduce the total number of Registrable Securities to be registered
on behalf of the Investor, until such time as the Staff or the SEC does not require such identification or until
the Investor accepts such identification and the manner thereof. If notwithstanding any such reduction, the Staff or the SEC still
requires that the Investor be specifically identified as an “underwriter” in order to permit such Registration Statement
to be declared effect, the Investor may, at its option, elect to have no Registrable Securities of the Investor be included in
such Registration Statement; provided, that solely for purposes of Section 12 of the Note, such Registration Statement shall be
deemed to have been declared effective as of the date of such election by the Investor.

 

    	4

    	 

    

 

Section
3.          Registration Procedures. If and whenever the Company
is required by the provisions of Section 2 to effect the registration of any Registrable Securities under the 1933 Act, the Company
will, as expeditiously as possible:

 

(a)          subject
to the timelines provided in this Agreement, prepare and file the Registration Statement with the SEC, with respect to such Registrable
Securities and use its reasonable best efforts to cause such Registration Statement to become and remain effective for the period
of the distribution contemplated thereby (determined as herein provided), respond as promptly as commercially practicable to any
comments received from the SEC with respect to a Registration Statement or any amendment thereto and file any pre-effective amendments
with respect to a Registration Statement as promptly as reasonable possible, and promptly provide to the Investor copies of all
filings and SEC letters of comment related to the Investor or the offering of the Registrable Securities (provided that the Company
shall excise any information contained therein which would constitute material non-public information regarding the Company or
any subsidiary) and notify the Investor (by telecopier or by e-mail addresses provided by the Investor) on or before the second
Business Day thereafter that the Company receives notice that (i) the SEC has no comments or no further comments on the registration
statement, and (ii) the registration statement has been declared effective;

 

(b)          prepare
and file with the SEC such amendments and supplements to such Registration Statement and the prospectus used in connection therewith
as may be necessary to keep such Registration Statement effective and prepare and file with the SEC such additional Registration
Statements as may be required hereunder and to keep each additional Registration Statement effective, in each case, at all times
during the Registration Period;

 

(c)          furnish
to the Investor such number of copies of the Registration Statement and the prospectus included therein (including each preliminary
prospectus) as the Investor reasonably may request in order to facilitate the public sale or their disposition of the securities
covered by such Registration Statement or make them electronically available;

 

(d)          use
its reasonable best efforts to register or qualify the Registrable Securities covered by such Registration Statement at all times
during the Registration Period under the securities or “Blue Sky” laws of such jurisdictions as the Investor shall
request in writing, provided, however, that the Company shall not for any such purpose be required to qualify to transact business
as a foreign corporation in any jurisdiction where it is not so qualified or to consent to service of process in any such jurisdiction;

 

(e)          if
applicable, list the Registrable Securities covered by such Registration Statement with the principal market or exchange on which
the Common Stock is then listed;

 

    	5

    	 

    

 

(f)          promptly
notify the Investor of the Company’s becoming aware that a prospectus relating thereto is required to be delivered under
the 1933 Act, of the happening of any event or passage of time of which the Company has knowledge as a result of which the prospectus
contained in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state
a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances
then existing or the financial statements included therein ineligible for inclusion or which becomes subject to a SEC, state or
other governmental order suspending the effectiveness of the Registration Statement covering any of the Registrable Securities.
The Investor hereby covenants that it will not sell any Registrable Securities pursuant to such prospectus during the period commencing
at the time at which the Company gives the Investor notice of the suspension of the use of such prospectus in accordance with this
Section 3(f) and ending at the time the Company gives the Investor notice that the Investor may thereafter effect sales pursuant
to the prospectus, or until the Company delivers to the Investor or files with the SEC an amended or supplemented prospectus.

 

(g)          The
Company shall cooperate with any broker-dealer through which the Investor proposes to resell its Registrable Securities in effecting
a filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110, as requested by any the Investor, and the Company
shall pay the filing fee required by such filing within two (2) Business Days of request therefor.

 

Section
4.          Provision of Documents. It shall be a condition precedent
to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities
of the Investor that the Investor shall furnish to the Company such information regarding itself, the Registrable Securities held
by it and the intended method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect
and maintain the effectiveness of the registration of such Registrable Securities and shall execute such documents in connection
with such registration as the Company may reasonably request.

 

Section
5.          Expenses. All expenses incurred by the Company in complying
with Section 2, including, without limitation, all registration and filing fees, printing expenses (if required), fees and disbursements
of counsel and independent public accountants for the Company, fees and expenses (including reasonable counsel fees) incurred in
connection with complying with state securities or “Blue Sky” laws, fees of the Financial Industry Regulatory Authority,
Inc. (“FINRA”) in connection with any filing with FINRA pursuant to FINRA Rule 5110 that may be required
to be made by any broker through which the Investor intends to make sales of Registrable Securities, transfer taxes, and fees of
transfer agents and registrars, are called “Registration Expenses.” The Company will pay all Registration
Expenses in connection with any Registration Statement described in Section 2.

 

    	6

    	 

    

 

Section
6.          Indemnification.

 

(a)          In
the event any Registrable Securities are included in any Registration Statement under this Agreement, to the fullest extent permitted
by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor, each of its directors, officers, shareholders,
members, partners, employees, agents, advisors, representatives (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding the lack of such title or any other title) and each Person, if any, who controls the
Investor within the meaning of Section 15 of the 1933 Act or Section 20 of the Securities Exchange Act of 1934 Act, as amended
(the “1934 Act”), and each of the directors, officers, shareholders, members, partners, employees, agents,
advisors, representatives (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
the lack of such title or any other title) of such controlling Persons (each, an “Investor Party” and
collectively, the “Investor Parties”), against any losses, obligations, claims, damages, liabilities,
contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs, reasonable attorneys’
fees, costs of defense and investigation), amounts paid in settlement or expenses, joint or several, (collectively, “Claims”)
incurred in investigating, preparing or defending any action, claim, lawsuit, inquiry, proceeding, investigation or appeal taken
from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether
pending or threatened, whether or not an Investor Party is or may be a party thereto (“Indemnified Damages”),
to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in
respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration
Statement or any post-effective amendment thereto or in any filing made in connection with the qualification of the offering under
the securities or other “Blue Sky” laws of any jurisdiction in which Registrable Securities are offered (“Blue
Sky Filing”), or the omission or alleged omission to state a material fact required to be stated therein or necessary
to make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement of a material fact contained
in any prospectus (as amended or supplemented) or in any prospectus supplement or the omission or alleged omission to state therein
any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein
were made, not misleading (the matters in the foregoing clauses (i) and (ii) being, collectively, “Violations”).
Subject to Section 6(c), the Company shall reimburse the Investor Parties, promptly as such expenses are incurred and are due and
payable, for any legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such
Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a):
(i) shall not apply to a Claim by an Investor Party arising out of or based upon a Violation which occurs in reliance upon and
in conformity with information furnished in writing to the Company by the Investor Party for the Investor Party expressly for use
in connection with the preparation of such Registration Statement, prospectus or prospectus supplement or any such amendment thereof
or supplement thereto; (ii) shall not be available to the Investor to the extent such Claim is based on a failure of the Investor
to deliver or to cause to be delivered the prospectus (as amended or supplemented) made available by the Company (to the extent
applicable), including, without limitation, a corrected prospectus, if such prospectus (as amended or supplemented) or corrected
prospectus was timely made available by the Company pursuant to Section 3 and then only if, and to the extent that, following the
receipt of the corrected prospectus no grounds for such Claim would have existed; and (iii) shall not apply to amounts paid in
settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not
be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made
by or on behalf of the Investor Party and shall survive the transfer of any of the Registrable Securities by the Investor pursuant
to Section 8(f).

 

    	7

    	 

    

 

(b)          In
connection with any Registration Statement in which the Investor is participating, the Investor agrees to severally and not jointly
indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company, each
of its directors, each of its officers who signs the Registration Statement and each Person, if any, who controls the Company within
the meaning of the 1933 Act or the 1934 Act (each, an “Company Party”), against any Claim or Indemnified
Damages to which any of them may become subject, under the 1933 Act, the 1934 Act or otherwise, insofar as such Claim or Indemnified
Damages arise out of or are based upon any Violation, in each case, to the extent, and only to the extent, that such Violation
occurs in reliance upon and in conformity with written information relating to the Investor furnished to the Company by the Investor
expressly for use in connection with such Registration Statement; and, subject to Section 6(c) and the below provisos in this Section
6(b), the Investor will reimburse a Company Party any legal or other expenses reasonably incurred by such Company Party in connection
with investigating or defending any such Claim; provided, however, the indemnity agreement contained in this Section
6(b) and the agreement with respect to contribution contained in Section 7 shall not apply to amounts paid in settlement of any
Claim if such settlement is effected without the prior written consent of the Investor, which consent shall not be unreasonably
withheld or delayed, provided further that the Investor shall be liable under this Section 6(b) for only that amount of a Claim
or Indemnified Damages as does not exceed the net proceeds to the Investor as a result of the applicable sale of Registrable Securities
pursuant to such Registration Statement. Such indemnity shall remain in full force and effect regardless of any investigation made
by or on behalf of such Company Party and shall survive the transfer of any of the Registrable Securities by the Investor pursuant
to Section 8(f).

 

    	8

    	 

    

 

(c)          Promptly
after receipt by an Investor Party or Company Party (as the case may be) under this Section 6 of notice of the commencement of
any action or proceeding (including, without limitation, any governmental action or proceeding) involving a Claim, the Investor
Party or Company Party (as the case may be) shall, if a Claim in respect thereof is to be made against any indemnifying party under
this Section 6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall
have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the
Investor Party or the Company Party (as the case may be); provided, however, an Investor Party or Company Party (as
the case may be) shall have the right to retain its own counsel with the fees and expenses of such counsel to be paid by the indemnifying
party if: (i) the indemnifying party has agreed in writing to pay such fees and expenses; (ii) the indemnifying party shall have
failed promptly to assume the defense of such Claim and to employ counsel reasonably satisfactory to the Investor Party or Company
Party (as the case may be) in any such Claim; or (iii) the named parties to any such Claim (including, without limitation, any
impleaded parties) include both the Investor Party or Company Party (as the case may be) and the indemnifying party, and the Investor
Party or such Company Party (as the case may be) shall have been advised by counsel that a conflict of interest is likely to exist
if the same counsel were to represent the Investor Party or such Company Party and the indemnifying party (in which case, if the
Investor Party or such Company Party (as the case may be) notifies the indemnifying party in writing that it elects to employ separate
counsel at the expense of the indemnifying party, then the indemnifying party shall not have the right to assume the defense thereof
on behalf of the indemnified party and such counsel shall be at the expense of the indemnifying party, provided further that in
the case of clause (iii) above the indemnifying party shall not be responsible for the reasonable fees and expenses of more than
one (1) separate legal counsel for all Investor Parties or Company Parties (as the case may be). The Company Party or Investor
Party (as the case may be) shall reasonably cooperate with the indemnifying party in connection with any negotiation or defense
of any such action or Claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available
to the Company Party or Investor Party (as the case may be) which relates to such action or Claim. The indemnifying party shall
keep the Company Party or Investor Party (as the case may be) reasonably apprised at all times as to the status of the defense
or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim
or proceeding effected without its prior written consent; provided, however, the indemnifying party shall not unreasonably
withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent of the Company Party or
Investor Party (as the case may be), consent to entry of any judgment or enter into any settlement or other compromise which does
not include as an unconditional term thereof the giving by the claimant or plaintiff to such Company Party or Investor Party (as
the case may be) of a release from all liability in respect to such Claim or litigation, and such settlement shall not include
any admission as to fault on the part of the Company Party. For the avoidance of doubt, the immediately preceding sentence shall
apply to Sections 6(a) and 6(b) hereof. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated
to all rights of the Company Party or Investor Party (as the case may be) with respect to all third parties, firms or corporations
relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party
within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the
Investor Party or Company Party (as the case may be) under this Section 6, except to the extent that the indemnifying party is
materially and adversely prejudiced in its ability to defend such action.

 

(d)          No
Person involved in the sale of Registrable Securities who is guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the 1933 Act) in connection with such sale shall be entitled to indemnification from any Person involved in such sale
of Registrable Securities who is not guilty of fraudulent misrepresentation.

 

(e)          The
indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred; provided that the Investor shall promptly
reimburse the Company for all such payments to the extent a court of competent jurisdiction determines that any Investor Party
was not entitled to such payments.

 

(f)          The
indemnity and contribution agreements contained herein shall be in addition to (i) any cause of action or similar right of the
Company Party or Investor Party against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be
subject to pursuant to the law.

 

    	9

    	 

    

 

Section
7.          Contribution. To the extent any indemnification by
an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided,
however: (i) no contribution shall be made under circumstances where the maker would not have been liable for indemnification
under the fault standards set forth in Section 6 of this Agreement, (ii) no Person involved in the sale of Registrable Securities
which Person is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) in connection with
such sale shall be entitled to contribution from any Person involved in such sale of Registrable Securities who was not guilty
of fraudulent misrepresentation; and (iii) contribution by any seller of Registrable Securities shall be limited in amount to the
amount of net proceeds received by such seller from the applicable sale of such Registrable Securities pursuant to such Registration
Statement. Notwithstanding the provisions of this Section 7, the Investor shall not be required to contribute, in the aggregate,
any amount in excess of the amount by which the net proceeds actually received by the Investor from the applicable sale of the
Registrable Securities subject to the Claim exceeds the amount of any damages that the Investor has otherwise been required to
pay, or would otherwise be required to pay under Section 6(b), by reason of such untrue or alleged untrue statement or omission
or alleged omission.

 

Section
8.          Miscellaneous.

 

(a)          Remedies.
In the event of a breach by the Company or by the Investor of any of their respective obligations under this Agreement, the Investor
or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement,
including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company
and the Investor agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach
by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance
in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.

 

(b)          Compliance.
The Investor covenants and agrees that it will comply with the prospectus delivery requirements of the 1933 Act as applicable to
it or an exemption therefrom in connection with sales of Registrable Securities pursuant to a Registration Statement.

 

(c)          Piggy-Back
Registrations. If, at any time prior to the six month anniversary of the date hereof, there is not an effective Registration
Statement covering all of the Registrable Securities and the Company shall determine to prepare and file with the SEC a registration
statement relating to an offering for its own account or the account of others under the 1933 Act of any of its equity securities,
other than on Form S-4 or Form S-8 (each as promulgated under the 1933 Act) or their then equivalents relating to equity securities
to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with
the Company’s stock option or other employee benefit plans, then the Company shall deliver to the Investor a written notice
of such determination and, if within fifteen days after the date of the delivery of such notice, the Investor shall so request
in writing, the Company shall include in such registration statement all or any part of such Registrable Securities the Investor
requests to be registered; provided, however, that the Company shall not be required to register any Registrable Securities pursuant
to this Section 8(c) that are the subject of a then effective Registration Statement.

 

    	10

    	 

    

 

(d)          Amendments
and Waivers. No provision of this Agreement may be (i) amended other than by a written instrument signed by both parties hereto
or (ii) waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. Failure
of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or
remedy, shall not operate as a waiver thereof.

 

(e)          Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as
set forth in the Securities Purchase Agreement.

 

(f)          Successors
and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each
of the parties. The Company may not assign (except by merger) its rights or obligations hereunder without the prior written consent
of the Investor. The Investor may assign its rights hereunder if: (i) the Investor agrees in writing with such transferee or assignee
(as the case may be) to assign all or any portion of such rights, and a copy of such agreement is furnished to the Company within
a reasonable time after such transfer or assignment (as the case may be); (ii) the Company is, within a reasonable time after such
transfer or assignment (as the case may be), furnished with written notice of (a) the name and address of such transferee or assignee
(as the case may be), and (b) the securities with respect to which such registration rights are being transferred or assigned (as
the case may be); (iii) immediately following such transfer or assignment (as the case may be) the further disposition of such
securities by such transferee or assignee (as the case may be) is restricted under the 1933 Act or applicable state securities
laws if so required; (iv) at or before the time the Company receives the written notice contemplated by clause (ii) of this sentence
such transferee or assignee (as the case may be) agrees in writing with the Company to be bound by all of the provisions contained
herein; (v) such transfer or assignment (as the case may be) shall have been made in accordance with the applicable requirements
of the Securities Purchase Agreement and the Note and/or Warrant, as applicable; and (vi) such transfer or assignment (as the case
may be) shall have been conducted in accordance with all applicable federal and state securities laws. The term “Investor”
in this Agreement shall also include all such transferees and assignees.

 

(g)          Execution
and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if
such facsimile or “.pdf” signature page were an original thereof.

 

(h)          Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined
in accordance with the provisions of the Securities Purchase Agreement.

 

    	11

    	 

    

 

(i)          Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their reasonable best
efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such
term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.

 

(j)          Headings.
The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit
or affect any of the provisions hereof.

 

(Signature Pages Follow)

 

    	12

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Registration Rights Agreement as of the date first written above.

 

	 	SKYLINE MEDICAL INC.
	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:	 

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Registration Rights Agreement as of the date first written above.

 

	 	[●]
	 	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:EXHIBIT 4.4 

 

[FORM OF WAIVER AND CONSENT OF, AND
NOTICE TO, HOLDER

OF PREFERRED STOCK OF SKYLINE MEDICAL
INC. (this “Consent”)]

 

Dated
as of July ___, 2014

 

Reference is made to that
certain (1) Certificate of Designation of Preferences, Rights and Limitations of Series A Senior Convertible Preferred Stock of
Skyline Medical Inc., a Delaware corporation (the “Company”), filed with the Delaware Secretary of State on
January 24, 2014 (the “Certificate”) and (2) Securities Purchase Agreement, dated as of February 4, 2014, by
and among the Company, the undersigned purchaser and the other purchasers (collectively, the “Purchasers”) named
on Schedule I thereto (the “Agreement”). All capitalized terms used but not defined herein shall have the respective
meanings set forth in the Certificate.

 

The Company has advised
the undersigned that the Company has executed a term sheet pursuant to which the Company intends to issue and sell (i) a note in
an original principal amount of $610,978 in a private placement transaction with 31 Group, LLC, comprised of, among others, Magna
Group, LLC and Aegis Capital Corp., for a purchase price of $500,000, (ii) one or more notes in an aggregate original principal
amount of up to $1,221,956 in a private placement transaction with certain affiliates of the Company and certain persons with whom
the Company has a pre-existing relationship, for an aggregate purchase price of up to $1,000,000 and (iii) one or more warrants
to purchase Common Stock in private placement transactions with 31 Group, LLC, certain affiliates of the Company and certain persons
with whom the Company has a pre-existing relationship (clauses (i), (ii) and (iii) collectively referred to herein as the “Additional
Financing”).  The Company has agreed to file a registration statement covering
the resale of the Common Stock issuable or issued and sold in connection with the Additional Financing (the “Additional
Securities”). Upon request, the Company will send the draft transaction documents for the Additional Financing to the
Purchasers. In order to facilitate the Additional Financing, the Company hereby requests the following from the undersigned:

 

		·	a waiver of the Company’s obligation under Section 6.12 of the Agreement to not enter into any
contract, transaction or arrangement or issue any security or instrument that provides for forward pricing of shares of Common
Stock (the “Forward Pricing Transaction Restriction”) with respect to the Additional Financing and, following
a Qualified Public Offering (as defined below), a waiver of the Forward Pricing Transaction Restriction for any subsequent offering
of securities by the Company;

 

		·	a consent to the inclusion of the registration of the Additional Securities on a registration statement
or registration statements of the Company to be filed under the Securities Act of 1933, as amended, pursuant to Section 10 of the
Agreement (the “Registration Statement”), covering the “Registrable Securities” as defined under
the Agreement (the “Purchasers Registrable Securities”);

 

    	 

    	 

    

 

		·	a consent to further extend the Filing Deadline and the Effectiveness Deadline pursuant to Section
10.1 of the Agreement such that the deadlines for the filing and effectiveness of the Registration Statement shall be the same
as the applicable deadlines for the Additional Financing; and

 

		·	an agreement by the undersigned that, (A) without the prior written consent of the underwriters, it
or its affiliates will not, directly or indirectly, for a period of 90 days from the closing of an underwritten public offering
of the Common Stock with gross offering proceeds of at least $6.0 million and the concurrent listing of the Common Stock on a national
securities exchange (a “Qualified Public Offering”), (i) offer, pledge, sell, contract to sell, sell any option
or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise
transfer or dispose of, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable
for shares of capital stock of the Company or (ii) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described
in clause (i) or (ii) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in
cash or otherwise, and (B) if requested by the underwriters in such Qualified Public Offering, it will execute a standard lock-up
agreement in the same form as executed by the Company’s officers and directors, solely to reflect the lock-up provided for
in clause (A) above, which agreement will become effective at the closing of such Qualified Public Offering (clauses (A) and (B)
together referred to herein as the “Purchaser Lock-Up”).

 

The undersigned hereby (i)
consents to waive the Forward Pricing Transaction Restriction with respect to the Additional Financing pursuant to Section 14.1
of the Agreement and waive it for all securities offerings subsequent to a Qualified Public Offering, (ii) consents to the registration
of the Additional Securities on the Registration Statement pursuant to Section 10.1 of the Agreement, (iii) consents to waive the
Filing Deadline and the Effectiveness Deadline pursuant to Section 10.1 of the Agreement, provided that the Registration Statement
covering the Purchasers Registrable Securities satisfies the applicable registration requirements relating to the Additional Financing
and (iv) agrees to comply with the Purchaser Lock-Up. 

 

In consideration for the waiver
and consents provided herein by the Purchasers:

 

(A) upon the closing
of a Qualified Public Offering, all outstanding shares of the Preferred Stock shall be automatically converted into shares of Common
Stock at the then applicable Conversion Price on the terms provided in this instrument and otherwise as if such conversion were
made by the Holders pursuant to the Certificate (such shares, the “Automatic Conversion Amount”), and this Consent
serves as the Company’s notice to the Holders of such conversion for all purposes; provided, however, that to the extent
that (i) the Qualified Public Offering closes within six (6) months of the first closing of the Additional Financing (“Qualified
Public Offering Deadline”) and (ii) 70% of the public offering price per share of the Common Stock in the Qualified Public
Offering (the “QPO Discount Price”) is less than the Conversion Price floor contained in Section 7(e)(i) of
the Certificate (the “Conversion Price Floor”), the Company shall issue additional shares of Common Stock (the
“QPO True-Up Amount”) to the Holders pro rata such that the total number of shares of Common Stock received
by the Holders (consisting of the sum of the Automatic Conversion Amount and the QPO True-Up Amount) shall equal the quotient of
(i) the product of the Stated Value and the aggregate number of outstanding shares of Preferred Stock held by such Holders and
(ii) the QPO Discount Price.

 

    	-2-

    	 

    

 

(B) if a Qualified
Public Offering is not consummated by the Qualified Public Offering Deadline, then upon a Holder’s conversion of its shares
of Preferred Stock, the Company shall issue to such holder such number of shares of Common Stock as calculated using the then applicable
Conversion Price pursuant to the Certificate (“Base Conversion Amount”); provided, however, that to the extent
that 70% of the volume weighted average price of the Common Stock on the principal Trading Market of the Common Stock during the
ten Trading Days immediately preceding the Qualified Public Offering Deadline (“Non-QPO Discount Price”) is
less than the Conversion Price Floor, then upon each conversion of shares of Preferred Stock by a Holder, the Company shall issue
additional shares of Common Stock (the “Non-QPO True-Up Amount”) to such Holder such that the total number of
shares of Common Stock received by such Holder (consisting of the sum of the Base Conversion Amount and the Non-QPO True-Up Amount)
shall equal the quotient of (i) the product of the Stated Value and the aggregate number of shares of Preferred Stock that such
Holder elected to convert and (ii) the Non-QPO Discount Price.

 

(C) Whenever the
Company shall be required to issue and deliver shares for the Automatic Conversion Amount, the QPO True-Up Amount, or the Non-QPO
True-Up Amount, the Company shall issue and deliver such shares in accordance with the requirements of Section 6 of the Certificate
as if such shares were being issued upon conversion of the Preferred Stock in accordance with the Certificate.

 

(D) The Purchasers
shall have the right to participate in the Additional Financing specified in clause (ii) of the definition of that term, pro rata
up to an aggregate of $500,000 based on their respective interests in the Preferred Stock.

 

(E) The Company
shall pay on demand the reasonable attorneys’ fees and expenses of the Purchasers relating to (1) this instrument, not to
exceed $7,500 in total, (2) the negotiation, preparation or execution of any amendment, modification or waiver of, or consent with
respect to, any of the Transaction Documents that is requested by the Company, and (3) upon receipt of notice from the Purchasers
to the Company, any default or breach of any of the Company’s obligations set forth in any of the Transaction Documents,
but only for so long as such default or breach is not cured; provided however, that the Purchasers shall provide to the Company
(x) an estimated budget of such reasonable fees and expenses and (y) monthly invoices of such reasonable fees and expenses incurred
pursuant to this paragraph (E).

 

(F) The term “Underlying
Shares” when used in the Transaction Documents shall include the shares of Common Stock issuable or issued to the Purchasers
pursuant to this Consent (the “Additional Shares”).

 

    	-3-

    	 

    

 

(G) Representations
and Warranties by the Company. The Company represents and warrants to the Purchasers that the statements contained in this Section
(G) are true and correct as of the date the Company executes this Consent and will be true and correct as of the date this Consent
becomes effective by its terms:

 

(1)
Consents. Neither the execution, delivery or performance of this Consent by the Company, nor the consummation by it of the
obligations and transactions contemplated hereby (including, without limitation, the issuance, the reservation for issuance
and the delivery of the Additional Shares and the provision to the Purchasers of the rights contemplated by this Consent and
the Transaction Documents with respect to the Additional Shares) requires any consent of, authorization by, exemption from,
filing with or notice to any Governmental Entity or any other Person, other than filings required under applicable U.S.
federal and state securities laws.

 

(2)
Authorization; Enforcement. The Company has all requisite corporate power and has taken all necessary corporate action
required for the due authorization, execution, delivery and performance by the Company of this Consent and the consummation
of the transactions contemplated hereby (including, without limitation, the issuance, the reservation for issuance and the
delivery of the Additional Shares and the provision to the Purchasers of the rights contemplated by this Consent and the
Transaction Documents with respect to the Additional Shares). The execution, delivery and performance by the Company of this
Consent and the consummation by the Company of the transactions contemplated hereby (including, without limitation, the
issuance of the Additional Shares and the provision to the Purchasers of the rights contemplated by this Consent and the
Transaction Documents with respect to the Additional Shares), have been duly authorized by the Company’s board of
directors or a duly authorized committee thereof and no further consent or authorization of the Company, its board of
directors or its stockholders is required. This Consent has been duly executed and delivered by the Company, and this Consent
constitutes a legal, valid and binding obligation of the Company enforceable against it in accordance with its terms, except
to the extent that enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally,
and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable
remedies.

 

(3) Valid
Issuance of Additional Shares. The Additional Shares have been duly and validly authorized and, when issued upon conversion of
the related Preferred Shares in accordance with this Consent, the Additional Shares will be validly issued, fully paid and non-assessable,
and shall be free and clear of all Encumbrances, and will not be subject to preemptive rights or other similar rights of stockholders
of the Company.

 

    	-4-

    	 

    

 

(4) No
Conflicts. The execution, delivery and performance of this Consent and the consummation of the transactions contemplated hereby
(including, without limitation, the issuance, the reservation for issuance and the delivery of the Additional Shares and the provision
to the Purchaser of the rights contemplated by this Consent and the Transaction Documents with respect to the Additional Shares)
will not (a) result in a violation of the certificate of incorporation, as amended, the by-laws, as amended, or any equivalent
organizational document of the Company or any Subsidiary (the “Charter Documents”) or require the approval of
the Company’s stockholders, (b) violate, conflict with or result in the breach of the terms, conditions or provisions of
or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give rise to
any right of termination, acceleration or cancellation under, any material agreement, lease, mortgage, license, indenture, instrument
or other contract to which the Company or any Subsidiary is a party, (c) result in a violation of any law, rule, regulation, order,
judgment or decree (including, without limitation, U.S. federal and state securities laws and regulations and regulations of any
self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any Subsidiary or
by which any property or asset of the Company or any Subsidiary is bound or affected, (d) result in a violation of or require stockholder
approval under any rule or regulation of the OTCQB, or (e) result in the creation of any Encumbrance upon any of the Company’s
or any of its Subsidiary’s assets.

 

(5) Right
of First Refusal; Stockholders Agreement; Voting and Registration Rights. Except with respect to options, warrants and convertible
securities disclosed in the SEC Reports or as provided in the Agreement or this Consent and for the options granted under the Company’s
stock option plans disclosed in the SEC Reports and for the Additional Financing, the Company does not have any outstanding options
to purchase, or any right of first refusal, right of first offer, right of co-sale, stockholder rights plan, preemptive right or
other right to subscribe for or to purchase any securities or obligations convertible into, or any contracts or commitments to
issue or sell, shares of its capital stock or any such options, rights, convertible securities or obligations, or any registration
right regarding the securities of the Company. There are no provisions of the Charter Documents, and no Material Contracts, other
than the Agreement and this Consent, that (a) may affect or restrict the voting rights of any Purchaser with respect to the Additional
Shares in its capacity as a stockholder of the Company, (b) restrict the ability of any Purchaser, or any successor thereto or
assignee or transferee thereof, to transfer the Additional Shares, or (c) would adversely affect the Company’s or any Purchaser’s
right or ability to consummate the transactions contemplated by this Consent or comply with the terms of this Consent and the transactions
contemplated hereby. There are no securities or instruments issued by or to which the Company is a party containing anti-dilution
or similar provisions that will be triggered by the issuance of the Additional Shares and there are no registration rights that
will be triggered by the issuance of the Additional Shares.

 

(6) No
Integrated Offering. Neither the Company, any Subsidiary, nor any of the Company’s or any Subsidiary’s Affiliates or
any other Person acting on the Company’s or any Subsidiary’s behalf, has directly or indirectly engaged in any form
of general solicitation or general advertising with respect to the Additional Shares, nor have any of such Persons made any offers
or sales of any security of the Company, any Subsidiary or any of the Company’s or any Subsidiary’s Affiliates or solicited
any offers to buy any security of the Company, any Subsidiary or any of the Company’s or any Subsidiary’s Affiliates
under circumstances that would require registration of the Additional Shares under the Securities Act or any other securities laws
or cause this offering of the Additional Shares to be integrated with any prior offering of securities of the Company or any Subsidiary
for purposes of the Securities Act in any manner that would affect the validity of the private placement exemption under the Securities
Act for the offer and sale of the Additional Shares hereunder.

 

    	-5-

    	 

    

 

(7)
Brokers. There is no investment banker, broker, finder, financial advisor or other Person that has been retained by or is
authorized to act on behalf of the Company or any Subsidiary who might be entitled to any fee or commission in connection
with the transactions contemplated by this Consent.

 

(8)
Disclosure. The Company understands and confirms that the Purchasers will rely on the foregoing representations in effecting
transactions in securities of the Company. No representation or warranty by the Company contained in this Consent contains
any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which they were made, not misleading. The Company confirms that neither it nor
any of its officers or directors nor any other Person acting on its or their behalf has provided, and it has not authorized
any other Person to provide, any Purchaser or its respective agents or counsel with any information that it believes
constitutes material non-public information except insofar as the existence, provisions and terms of this Consent and the
proposed transactions hereunder may constitute such information, all of which will be disclosed by the Company in a press
release or SEC filing on Form 8-K.

 

(9)
Application of Takeover Protections. The Company and its Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a
rights agreement) or other similar anti-takeover provision under the Company’s Charter Documents or any stockholder
rights plan of the Company or the laws of its state of incorporation (including Section 203 of the Delaware General
Corporation Law) that is or could become applicable to each Purchaser as a result of such Purchaser and the Company
fulfilling their obligations or exercising their rights under this Consent, including, without limitation, as a result of the
Company’s issuance of the Additional Shares and any Purchaser’s ownership of the Additional Shares.

 

(10)
Private Placement. Neither the Company nor its Subsidiaries or any affiliates, nor any person acting on its or their behalf,
has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under any
circumstances that would require registration of the Additional Shares under the Securities Act. The issuance of the
Additional Shares is exempt from registration under the Securities Act.

 

(11)
Acknowledgment Regarding Purchasers’ Registration of Additional Shares. The Company acknowledges and agrees that each
of the Purchasers is acting solely in the capacity of an arm’s length party with respect to this Consent and the
transactions contemplated hereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or
fiduciary of the Company (or in any similar capacity with respect to the Company) with respect to this Consent and the
transactions contemplated hereby and any advice given by any Purchaser or any of their respective representatives or agents
to the Company in connection with this Consent and the transactions contemplated hereby is merely incidental to such
Purchaser’s negotiating and executing this Consent. The Company further represents to each Purchaser that the
Company’s decision to enter into this Consent has been based on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.

 

    	-6-

    	 

    

 

 

(12) No
Registration Rights. No person has the right to (i) prohibit the Company from filing a Registration Statement or (ii) require the
Company to register any securities for sale under the Securities Act by reason of the filing of a Registration Statement except
in the case of clause (ii) for rights which have been disclosed in the SEC Reports, rights which have been properly waived and
rights that the Company may grant to investors in the Additional Financing. The granting and performance of the registration rights
under the Agreement that are applicable to the Additional Shares will not violate or conflict with, or result in a breach of any
provision of, or constitute a default under, any agreement, indenture, or instrument to which the Company is a party.

 

(13) No
Additional Agreements. The Company has no other agreements or understandings (including, without limitation, side letters) with
any Purchaser to purchase or otherwise acquire shares of Common Stock on terms other than as set forth herein and in the Transaction
Documents.

 

This Consent shall serve as the Company’s
notice to the Holders of the adjustment to the Conversion Price in connection with the Additional Financing for purposes of Section
7(g)(i) of the Certificate. The Conversion Price shall be adjusted to equal the conversion price set forth in the definitive documentation
for the Additional Financing.

 

This Consent shall become effective:

 

1. only in accordance with Section 14.1
of the Agreement and then only upon the first closing of the Additional Financing; and

 

2. when the Company shall have delivered
to each Purchaser a certificate of the Secretary of the Company certifying the resolutions duly adopted by the board of directors
of the Company or a duly authorized committee thereof approving the transactions contemplated by this Consent and the issuance
of the Additional Shares, and such resolutions shall be reasonably satisfactory in form, scope and substance to the Required Holders.

 

From and after the effective day of this
Consent, each reference in the Transaction Documents to the Agreement shall be deemed a reference to the Agreement as modified
by the consent of the Purchasers relating to the Agreement and given in May 2014 and by this Consent.

 

This Consent may be signed by the Purchasers
and the Company in counterparts. Except as expressly modified hereby, the Agreement and the Certificate remain in full force and
effect in accordance with their terms, and the other Transaction Documents remain in full force and effect.

 

[Signature Page follows]

 

    	-7-

    	 

    

 

IN WITNESS WHEREOF, the parties hereto,
by their officers thereunto duly authorized or in their individual capacity, as the case may be, have executed this Consent under
seal as of the day and year first above written.

 

	 	THE COMPANY:
	 	 
		Skyline Medical Inc.
	 	 
	 	By:	 
	 	Name:
		Title:

  

Accepted and Agreed:

 

	INDIVIDUAL STOCKHOLDERS	 	ENTITY STOCKHOLDERS
	 	 	 
	 	 	 
	 	 	Name of Entity
	 	 	 
	Signature (Individual)	 	By:	 
	 	 	 	Signature
	 	 	Its:	 
	Signature	 		Title
	(all record holders should sign)	 	 	
	 	 	 
	 	 	 
	Names(s) Typed or Printed	 	Signatory Name Typed or Printed
	 	 	 
	Dated:	 	Dated:
	 	 	 

 

[Signature Page to Waiver and Consent of
Preferred Stockholders]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]